Abstract | OBJECTIVE: METHODS: Patients in two uniform groups (Groups A and B, each of which had 10 patients with histologically confirmed glioblastomas) received BSH at a dose used in earlier therapeutic trials (75 mg/kg of body weight, administered intravenously) 24 hours before surgical debulkment. Patients from Group B received additional hyaluronidase (200,000 IU, administered intravenously) immediately before BSH infusion. Boron concentrations were analyzed by inductively coupled plasma-atomic emission spectroscopy. RESULTS: The application of hyaluronidase was associated with a statistically significant improvement in the tumor (maximum)-to-blood concentration ratio of 1.83 (range, 0.68-3.67) compared with 1.31 (range, 0.8-1.78) with BSH alone. Moreover, with the use of hyaluronidase, there was a tendency for a higher maximal concentration in tumor (not statistically significant). Boron accumulation in glioblastoma tissue was highly selective in both groups, with tumor-to-healthy brain concentration ratios ranging from 6:1 to 20:1. CONCLUSION: These preliminary data suggest that hyaluronidase improves BSH biodistribution and, consequently, the therapeutic potential of this boron carrier. This finding might be of clinical value in the future.
|
Authors | K Haselsberger, H Radner, G Pendl |
Journal | Neurosurgery
(Neurosurgery)
Vol. 39
Issue 2
Pg. 321-5; discussion 325-6
(Aug 1996)
ISSN: 0148-396X [Print] United States |
PMID | 8832669
(Publication Type: Journal Article)
|
Chemical References |
- Borohydrides
- Radiation-Sensitizing Agents
- Sulfhydryl Compounds
- mercaptoundecahydrododecaborate
- Hyaluronoglucosaminidase
|
Topics |
- Adult
- Aged
- Biological Availability
- Blood-Brain Barrier
(drug effects, physiology)
- Borohydrides
(administration & dosage, pharmacokinetics)
- Boron Neutron Capture Therapy
(methods)
- Brain Neoplasms
(pathology, radiotherapy, surgery)
- Combined Modality Therapy
- Craniotomy
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Female
- Glioblastoma
(pathology, radiotherapy, surgery)
- Humans
- Hyaluronoglucosaminidase
(administration & dosage, pharmacokinetics)
- Infusions, Intravenous
- Male
- Middle Aged
- Radiation-Sensitizing Agents
(administration & dosage, pharmacokinetics)
- Radiotherapy, Adjuvant
- Sulfhydryl Compounds
(administration & dosage, pharmacokinetics)
|